Updated
The most significant concentration Zura Bio discloses is ZB Assets (tibulizumab, torudokimab, crebankitug), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Zura Bio’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'We are substantially dependent on the success of the ZB Assets, and our ongoing and anticipated clinical trials of the ZB Assets may not be successful.'”
“10-K Item 1A: 'We depend on license agreements with Pfizer Inc. and their wholly owned subsidiaries (“Pfizer”) and Eli Lilly and Company and their wholly owned subsidiaries (“Lilly”) to permit us to use certain patents, know-how and technology.'”
Zura Bio's concentration risk combines early-stage pipeline dependency with external licensing dependency. The company states it is substantially dependent on the success of the ZB Assets — tibulizumab, torudokimab, and crebankitug — and that its ongoing and anticipated clinical trials of these assets may not be successful, a high-share exposure with a mixed character reflecting both the structural reality of a single-franchise pipeline and the binary nature of clinical trial outcomes. Compounding that is a second high-share exposure: Zura depends on license agreements with Pfizer and Eli Lilly to use certain patents, know-how, and technology underlying its programs, a dependency on two external counterparties for the underlying intellectual property rather than outright ownership. Together, these two exposures stack rather than diversify: even if the ZB Assets clear clinical hurdles, Zura's ability to commercialize them remains contingent on the continued good standing of its licensing arrangements with Pfizer and Lilly. With no disclosed secondary pipeline or alternative licensing source, both exposures are capable of independently moving the verdict, and their combination means Zura's investment case rests on both clinical success and licensing continuity holding simultaneously.
For the engine’s reasoning on ZURA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ZURA● | Zura Bio Limited | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.